Prolonged survival in patients with hand-foot skin reaction secondary to cooperative sorafenib treatment

Table 7 Prognostic factors of time-to-treatment failure by multivariable Cox regression analysis

		Univariate analysis			Multivariate analysis
	HR	95%CI	P value	HR	95%CI	P value
Age (within 70 yr)	1.059	0.747–1.501	0.747	-	-	-
Male	0.926	0.625–1.372	0.703	-	-	-
Etiology (HBV)	1.208	0.768–1.901	0.413	-	-	-
BCLC stage C	1.311	0.921–1.866	0.132	-	-	-
Portal vein thrombosis	1.379	0.925–2.056	0.115	1.011	0.662–1.545	0.958
Diarrhea	0.675	0.473–0.965	0.031	0.654	0.449–0.952	0.027
Hypertension	1.070	0.735–1.556	0.725	-	-	-
ECOG Performance status 1	0.687	0.446–1.058	0.089	0.725	0.463–1.135	0.159
Group B vs Group A	1.670	1.034–2.698	0.036	1.694	1.044–2.748	0.033
Group C vs Group A	0.495	0.328–0.747	< 0.001	0.529	0.346–0.811	0.003
Sorafenib administration period (second half vs first half)	0.980	0.694–1.384	0.908	-	-	-

AFP: Alpha-fetoprotein; BCLC: Barcelona Clinic Liver Cancer; HBV: Hepatitis B virus; ECOG: Eastern Cooperative Oncology Group.